JP2023544797A5 - - Google Patents
Info
- Publication number
- JP2023544797A5 JP2023544797A5 JP2023521295A JP2023521295A JP2023544797A5 JP 2023544797 A5 JP2023544797 A5 JP 2023544797A5 JP 2023521295 A JP2023521295 A JP 2023521295A JP 2023521295 A JP2023521295 A JP 2023521295A JP 2023544797 A5 JP2023544797 A5 JP 2023544797A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- approximately
- hours
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088826P | 2020-10-07 | 2020-10-07 | |
| US63/088,826 | 2020-10-07 | ||
| US202163147527P | 2021-02-09 | 2021-02-09 | |
| US63/147,527 | 2021-02-09 | ||
| PCT/US2021/053759 WO2022076549A1 (en) | 2020-10-07 | 2021-10-06 | Formulations for suprachoroidal administration such as high viscosity formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544797A JP2023544797A (ja) | 2023-10-25 |
| JP2023544797A5 true JP2023544797A5 (cg-RX-API-DMAC7.html) | 2024-03-06 |
Family
ID=78516913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521295A Pending JP2023544797A (ja) | 2020-10-07 | 2021-10-06 | 脈絡膜上投与用の、高粘度製剤などの製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240024508A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4225270A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023544797A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021358048A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198372A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004035A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228648A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022076549A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| TW202345913A (zh) * | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| AU2015316709B2 (en) | 2014-09-19 | 2020-03-26 | Oxular Limited | Ophthalmic delivery device |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療 |
| US10912883B2 (en) | 2017-11-04 | 2021-02-09 | Altaviz, Llc | Gas-powered fluid injection system |
-
2021
- 2021-10-06 TW TW110137245A patent/TW202228648A/zh unknown
- 2021-10-06 MX MX2023004035A patent/MX2023004035A/es unknown
- 2021-10-06 AU AU2021358048A patent/AU2021358048A1/en not_active Abandoned
- 2021-10-06 JP JP2023521295A patent/JP2023544797A/ja active Pending
- 2021-10-06 CA CA3198372A patent/CA3198372A1/en active Pending
- 2021-10-06 US US18/030,630 patent/US20240024508A1/en active Pending
- 2021-10-06 WO PCT/US2021/053759 patent/WO2022076549A1/en not_active Ceased
- 2021-10-06 EP EP21802478.4A patent/EP4225270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7733706B2 (ja) | 血管新生眼疾患を処置するためのvegfアンタゴニストの使用 | |
| US20240024508A1 (en) | Formulations for suprachoroidal administration such as high viscosity formulations | |
| US20230414788A1 (en) | Formulations for suprachoroidal administration such as gel formulations | |
| US20230372538A1 (en) | Formulations for suprachoroidal administration such as formulations with aggregate formation | |
| EP4027983B1 (en) | Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept | |
| KR20240145489A (ko) | 아플리베르셉트를 코딩하는 aav2 변이체를 사용하여 안구 신생혈관 질환을 치료하는 방법 | |
| JP2024148177A (ja) | アフリベルセプトをコードするaav2バリアントを使用する眼内血管新生疾患を処置する方法 | |
| Tu et al. | AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization | |
| US20250339555A1 (en) | Formulations for suprachoroidal administration such as formulations with aggregate formation | |
| US20260034243A1 (en) | Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration | |
| CN116546975A (zh) | 用于脉络膜上施用的制剂诸如高粘度制剂 | |
| CN116635004A (zh) | 用于脉络膜上施用的制剂如凝胶制剂 | |
| CN116601299A (zh) | 用于脉络膜上施用的制剂诸如具有聚集体形成的制剂 | |
| WO2023196835A1 (en) | Formulations for suprachoroidal administration such as gel formulations | |
| HK40077797B (en) | Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept | |
| HK40077797A (en) | Treatment of ocular neovascular diseases using aav2 variants encoding aflibercept |